Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Soliton Inc (SOLY)

Soliton Inc (SOLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 242,297
  • Shares Outstanding, K 16,932
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,310 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 30.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.61 +33.65%
on 12/30/19
15.00 -5.47%
on 01/22/20
+3.25 (+29.73%)
since 12/20/19
3-Month
9.85 +43.96%
on 11/07/19
15.39 -7.86%
on 10/23/19
-0.59 (-3.99%)
since 10/22/19

Most Recent Stories

More News
Soliton To Announce Keloid and Hypertrophic Scar Clinical 12-Week Trial Data at Maui Derm Meeting

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson...

SOLY : 14.18 (-0.91%)
Soliton Appoints Robert "Joe" Mills as Vice President of Supply Chain

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson...

SOLY : 14.18 (-0.91%)
Why the U.S. Remains the Largest Market for Medical Devices

Back in the end of 2018, a report from Moody's said that 2019 should be a standout year for the medical device industry. They added that revenue growth for device companies would be driven through innovation...

SOLY : 14.18 (-0.91%)
ATEC : 6.74 (-1.46%)
MDT : 121.09 (+0.64%)
IMGN : 4.68 (-0.43%)
ACST : 0.71 (+3.80%)
ACST.VN : 0.920 (+2.22%)
Soliton Announces Successful Completion of Safety Testing at SGS to Support FDA Filing for Second Generation Device

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson...

SOLY : 14.18 (-0.91%)
Soliton Appoints Mary Stoll as Senior Director of Clinical Development

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson...

SOLY : 14.18 (-0.91%)
Soliton Initiates Significant Step Towards Commercialization

Medical device innovation company Soliton, Inc. (Nasdaq: SOLY) today announced that it has engaged Tailfin, an Atlanta based brand and marketing firm, to help develop brand strategy and marketing and sales...

SOLY : 14.18 (-0.91%)
Soliton and Emphysys Enter Into a 3-year Development Agreement

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson...

SOLY : 14.18 (-0.91%)
Soliton Announces First Follow-up Visit Conducted in the Pivotal Cellulite Clinical Trial

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson...

SOLY : 14.18 (-0.91%)
Soliton Completes Treatment of All Patients in Pivotal Cellulite Trial

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson...

SOLY : 14.18 (-0.91%)
Soliton's Recent Positive Data Increases Potential Fibrotic Indications

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson...

SOLY : 14.18 (-0.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade SOLY with:

Business Summary

Soliton Inc. is a medical device company. Its commercial product uses rapid pulses of designed acoustic shockwaves to dramatically accelerate the removal of unwanted tattoos. Soliton Inc. is based in Houston, Texas.

See More

Key Turning Points

2nd Resistance Point 15.37
1st Resistance Point 14.77
Last Price 14.18
1st Support Level 13.81
2nd Support Level 13.45

See More

52-Week High 29.00
Fibonacci 61.8% 19.50
Fibonacci 50% 16.56
Last Price 14.18
Fibonacci 38.2% 13.62
52-Week Low 4.12

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar